BamSEC and AlphaSense Join Forces
Learn More

Mineralys Therapeutics Inc.

NASDAQ: MLYS    
Share price (3/26/25): $16.15    
Market cap (3/26/25): $805 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.12
from 10-K 34 pages Eligibility
12/34/56
EX-10.1
from 8-K 32 pages Mineralys Therapeutics, Inc. Securities Purchase Agreement
12/34/56
EX-10.7
from S-1/A 11 pages February 1, 2023 Adam Levy Re: Amended and Restated Employment Letter Dear Adam
12/34/56
EX-10.6
from S-1/A 11 pages February 1, 2023 David Rodman, M.D. Re: Amended and Restated Employment Letter Dear Dr. Rodman
12/34/56
EX-10.5
from S-1/A 11 pages February 1, 2023 Jon Congleton Re: Amended and Restated Employment Letter Dear Jon
12/34/56
EX-10.4
from S-1/A 3 pages Mineralys Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.3
from S-1/A 15 pages Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 37 pages Eligibility
12/34/56
EX-10.1
from S-1/A 19 pages Mineralys Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.9
from S-1 41 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. License Agreement
12/34/56
EX-10.8
from S-1 18 pages Indemnification and Advancement Agreement
12/34/56
EX-10.7
from S-1 10 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. March 8, 2022 via Email Adam Levy [***] Re: Employment Offer Letter Dear Adam: Mineralys Therapeutics, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”)
12/34/56
EX-10.6
from S-1 9 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. January 8th, 2021 via Email David Rodman, MD [***] Re: Employment Offer Letter Dear Dr. Rodman: Mineralys Therapeutics, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”)
12/34/56
EX-10.5
from S-1 9 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. October 9, 2020 via Email Jon Congleton [***] Re: Employment Offer Letter Dear Jon: Mineralys Therapeutics, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”)
12/34/56
EX-10.3
from S-1 15 pages Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1 37 pages Eligibility
12/34/56
EX-10.1
from S-1 19 pages Mineralys Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.9
from DRS 41 pages License Agreement
12/34/56
EX-10.7
from DRS 10 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. March 8, 2022 via Email Adam Levy [***] Re: Employment Offer Letter Dear Adam: Mineralys Therapeutics, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”)
12/34/56
EX-10.6
from DRS 9 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. January 8th, 2021 via Email David Rodman, MD [***] Re: Employment Offer Letter Dear Dr. Rodman: Mineralys Therapeutics, Inc. (The “Company”) Is Pleased to Offer You a Position on the Terms Set Forth in This Letter (This “Agreement”)
12/34/56